Recombinant human growth hormone was developed in the 1980s, following which it has been used worldwide for the treatment of short stature. Over the last almost 30 years, there has been increasing experience with the use of GH therapy for adults with confirmed GH deficiency, predominantly in the setting of known pituitary/hypothalamic disease. Many countries now support funded adult GH replacement therapy, including more recently Australia. New Zealand introduced nationally funded treatment for GH deficient adults in 2010. This talk will address the NZ experience with adult GH therapy, aiming to provide a practical perspective on treatment criteria, monitoring and outcomes.